PRINCETON, N.J., June 12, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc., (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, today announced that the Company will present at the BIO International Convention 2014 which is taking place from June 23-26 at the San Diego Convention Center in San Diego, CA. An overview of Advaxis will be presented on Tuesday, June 24, 2014 at 10:45 a.m. PT.
Greg Mayes, Executive Vice President and Chief Operating Officer of Advaxis, commented, "The BIO International Convention is the premier venue to pursue and attract strategic and business development partners. With our lead cancer immunotherapy, ADXS-HPV, potentially entering a pivotal phase 3 trial this year, we believe now is the time to attract interest from pharma companies longing for a de-risked, late-stage, value-creating asset. With our early stage assets, ADXS-PSA and ADXS-cHER2, we will be seeking partners that would be willing to co-develop these assets to confirm the safety profile and detect meaningful efficacy signals in an early stage trial. Partnering is critical for Advaxis so we can maximize the opportunities our cancer immunotherapy platform may potentially offer patients and investors."
About the BIO International Convention
The BIO International Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. The Convention also features the BIO Business Forum, a unique platform for biotechnology and pharmaceutical companies, academic research institutions, and investors from around the world to gather and discuss strategic opportunities. For registration, conference agenda and exhibitor information, visit convention.bio.org
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform intended to redirect the immune system to kill cancer. The Advaxis technology, using bioengineered live attenuated bacteria, is the only known cancer immunotherapy shown in preclinical studies to neutralize Tregs and MSDCs, that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis's lead immunotherapy, ADXS-HPV, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA has granted Advaxis orphan drug status for each of these three indications. The Company plans to initiate a registrational clinical program for cervical cancer in 2014 and has established licensing partners in India and Asia for commercialization in those regions. Advaxis's second immunotherapy candidate in clinical testing will be ADXS-PSA, which is being developed to address prostate cancer. Advaxis is planning to file an IND with the FDA and initiate a Phase 1 clinical study with ADXS-PSA in 2014. Advaxis is also developing ADXS-cHER2, to target the HER2 receptor, which is overexpressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, and gastric cancer. Advaxis is developing ADXS-cHER2 for both human and animal-health, and has seen promising results in canine osteosarcoma, which is considered a model for human bone cancer. Advaxis is pursuing a clinical program in pediatric osteosarcoma and has licensed ADXS-cHER2 and three other immunotherapy constructs to a major animal-health company. Advaxis is planning to file an IND for ADXS-cHER2 in HER2 overexpressing cancers.
For more information please visit www.advaxis.com or connect with us on
- Facebook: https://www.facebook.com/advaxisinc
- Twitter: https://twitter.com/Advaxis
- LinkedIn: http://www.linkedin.com/company/advaxis-inc.
- Google+: https://plus.google.com/b/115126287957745987074/115126287957745987074/posts
This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis's ability to develop the next generation of cancer immunotherapies; the safety and efficacy of Advaxis's proprietary immunotherapy, ADXS-HPV; whether higher doses and multiple treatment cycles of ADXS-HPV can further improve clinical outcomes and quality of life; Advaxis moving forward with a registration program in recurrent cervical cancer; the collaborative efforts of Advaxis's licensing partners; the initiation or a registration clinical trial program for cervical cancer in 2014; Advaxis's development of ADXS-cHER2 for both human and animal health and its pursuit of a clinical program in pediatric osteosarcoma. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis's SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2013, which is available at http://www.sec.gov. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.
CONTACT: Advaxis Contact: Lisa Caperelli Senior Director of Investor Relations and Corporate Communications Advaxis, Inc. firstname.lastname@example.org 215.206.1822 Media Contact: Tiberend Strategic Advisors, Inc. Amy S. Wheeler email@example.com 646.362.5750